Vanda Pharmaceuticals Inc. (VNDA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vanda Pharmaceuticals Inc. announced an update on the FDA’s review of their application for HETLIOZ® to treat insomnia, sharing the progress in a press release. This latest development could be a significant step for the company and is of interest to investors monitoring Vanda’s market movements.
For further insights into VNDA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.